medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2022, Number 4

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2022; 20 (4)

Botulinum toxin: Novel uses and evidence

Arias-Rodríguez C

Language: Spanish
References: 19
Page: 448-452
PDF size: 133.98 Kb.


ABSTRACT

Botulinum toxin is a neurotoxin produced by Clostridium botulinum, widely used in dermatology, aesthetic medicine, and other medical specialties. In the last years it’s been reported its efficiency in treating other dermatological disorders, including rosacea, oily skin and dilated pores, hypertrophic scars and keloids, among others. The objective of this literature revision is to make emphasis in those three conditions, explaining possible mechanisms of action and its actual evidence.


REFERENCES

  1. Alster TS y Harrison IS, Alternative clinical indications of botulinumtoxin, Am J Clin Dermatol 2020; 21(6):855-80.

  2. Naik PP, Utilities of botulinum toxins in dermatology and cosmetology,Clin Cosmet Investig Dermatol 2021; 14:1319-30.

  3. França K, Kumar A, Fioranelli M, Lotti T, Tirant M y Roccia MG, Thehistory of botulinum toxin: from poison to beauty, Wien Med Wochenschr2017; 167(S1):46-8.

  4. Ali FR y Al-Nuaimi F, Justinus Kerner and sausage poisoning: the birthof botulinum toxin, Int J Dermatol 2016; 55(11):1295-6.

  5. Guida S, Farnetani F, Nisticò SP, Mariarosaria CG, Babino G, PellacaniG et al., New trends in botulinum toxin use in dermatology, DermatolPract Concept 2018; 277-82.

  6. Kim Y, Hong E y Kim H, Botulinum toxin in the field of dermatology:novel indications, Toxins 2017; 9(12):403.

  7. Zhang H, Tang K, Wang Y, Fang R y Sun Q, Use of botulinum toxinin treating rosacea: a systematic review, Clin Cosmet Investig Dermatol2021; 14:407-17.

  8. Martina E, Diotallevi F, Radi G, Campanati A y Offidani A, Therapeuticuse of botulinum neurotoxins in dermatology: systematic review,Toxins 2021; 13(2):120.

  9. Kim MJ, Kim JH, Cheon HI, Hur MS, Han SH, Lee YW et al., Assessmentof skin physiology change and safety after intradermal injectionswith botulinum toxin: a randomized, double-blind, placebo-controlled,split-face pilot study in rosacea patients with facial erythema, DermatolSurg 2019; 45(9):1155-62.

  10. Park KY, Hyun MY, Jeong SY, Kim BJ, Kim MN y Hong CK, Botulinumtoxin for the treatment of refractory erythema and flushing of rosacea,Dermatology 2015; 230(4):299-301.

  11. Al-Niaimi F, Glagoleva E y Araviiskaia E, Pulsed dye laser followed byintradermal botulinum toxin type-a in the treatment of rosacea-associatederythema and flushing, Dermatol Ther 2020; 33(6). Disponibleen: https://onlinelibrary.wiley.com/doi/10.1111/dth.13976.

  12. Shuo L, Ting Y, KeLun W, Rui Z y Hang W, Efficacy and possiblemechanisms of botulinum toxin treatment of oily skin, J Cosmet Dermatol2019; 18(2):451-7.

  13. Campanati A, Martina E, Giuliodori K, Consales V, Bobyr I y Offidani A,Botulinum toxin off-label use in dermatology: a review, Skin AppendageDisord 2017 ;3(1):39-56.

  14. Shirshakova M, Morozova E, Sokolova D, Pervykh S y Smirnova L, Theeffectiveness of botulinum toxin type a (btx-a) in the treatment offacial skin oily seborrhea, enlarged pores, and symptom complex ofpost-acne, Int J Dermatol 2021; 60(10):1232-41.

  15. Park J-Y, Cho S, Hur K y Lee D, Intradermal microdroplet injection ofdiluted incobotulinumtoxin-a for sebum control, face lifting, and poresize improvement, J Drugs Dermatol, 2021; 20(1):49-54.

  16. Sayed KS, Hegazy R, Gawdat HI, Abdel Hay RM, Ahmed MM, MohammedFN et al., The efficacy of intradermal injections of botulinumtoxin in the management of enlarged facial pores and seborrhea: asplit face-controlled study, J Dermatol Treat 2021; 32(7):771-7.

  17. Elhefnawy A, Assessment of intralesional injection of botulinum toxintype a injection for hypertrophic scars, Indian J Dermatol Venereol Leprol2016; 82(3):279.

  18. Kasyanju Carrero LM, Ma W, Liu H, Yin X y Zhou B, Botulinum toxintype a for the treatment and prevention of hypertrophic scars andkeloids: updated review, J Cosmet Dermatol 2019; 18(1):10-5.

  19. Neinaa YM, Elsayed TA, Mohamed DA y Elfar NN, Botulinum toxinand platelet rich plasma as innovative therapeutic modalities for keloids,Dermatol Ther 2021; 34(3). Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/dth.14900.




2020     |     www.medigraphic.com